These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2733097)

  • 1. Enhanced anti-tumor effects of recombinant human tumor necrosis factor plus VP-16 on metastatic renal cell carcinoma in a xenograft model.
    Burgers JK; Marshall FF; Isaacs JT
    J Urol; 1989 Jul; 142(1):160-4. PubMed ID: 2733097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model.
    Donaldson JT; Keane TE; Poulton SH; Walther PJ
    Urol Res; 1990; 18(4):245-50. PubMed ID: 2219586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of a human renal cell carcinoma in nude mice with recombinant human tumor necrosis factor alpha and etoposide.
    Hofmockel G; Bassukas ID; Heimbach D; Wirth M; Maurer-Schultze B
    J Urol; 1993 Dec; 150(6):1974-9. PubMed ID: 8230548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on anti-tumor activity of tumor necrosis factor alpha against human renal cell carcinoma cells heterotransplanted into nude mice].
    Shibayama T; Tachibana M; Tazaki H; Nakamura K
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1611-9. PubMed ID: 1770700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on in vitro mechanisms of anti-tumor activity of the tumor necrosis factor alpha against human renal carcinoma cell line (KU-2).
    Shibayama T
    Keio J Med; 1989 Mar; 38(1):13-26. PubMed ID: 2716215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of biological response modifiers on growth and cell proliferation of human tumor xenografts in nude mice.
    Maurer-Schultze B; Bassukas ID; Hofmockel G
    Cell Mol Biol (Noisy-le-grand); 1995 Feb; 41(1):65-78. PubMed ID: 7773138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence.
    de Riese W; Goldenberg K; Allhoff E; Stief C; Schlick R; Liedke S; Jonas U
    Int Urol Nephrol; 1991; 23(1):13-25. PubMed ID: 1938215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemotherapy for murine bladder tumor with a new human recombinant tumor necrosis factor (rTNF-S), VP-16 and hyperthermia.
    Iizumi T; Yazaki T; Waku M; Soma G
    J Urol; 1989 Aug; 142(2 Pt 1):386-9. PubMed ID: 2746758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy in conjunction with surgery: strategies for management of murine neuroblastoma.
    Leonard MP; Gearhart JP; Jeffs RD
    J Pediatr Surg; 1991 Oct; 26(10):1224-9. PubMed ID: 1779333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative and cytotoxic effects of single and combined treatment with tumor necrosis factor alpha and/or alpha interferon on a human renal cell carcinoma xenotransplanted into nu/nu mice: cell kinetic studies.
    Baisch H; Otto U; Klöppel G
    Cancer Res; 1990 Oct; 50(19):6389-95. PubMed ID: 2400997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on in vitro anti-tumor activity of tumor necrosis factor alpha against human renal carcinoma cell line (KU-2)].
    Shibayama T; Tachibana M; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1603-10. PubMed ID: 1770699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
    Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
    Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma?
    Migliari R; Muscas G; Solinas A; Melis M; Ionta MT; Massidda B; Usai E
    J Chemother; 1995 Jun; 7(3):240-5. PubMed ID: 7562021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection.
    An Z; Jiang P; Wang X; Moossa AR; Hoffman RM
    Clin Exp Metastasis; 1999 May; 17(3):265-70. PubMed ID: 10432012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
    Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
    Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with tumor necrosis factor alpha and interferon alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon alpha.
    Bassukas ID; Hofmockel G; Maurer-Schultze B
    Anticancer Res; 1994; 14(1A):237-45. PubMed ID: 8166454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.